You are here

  • Home
  • Archive
  • Volume 20, Issue 5
  • Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

Article info

Article menu
Download PDFPDF
Ovarian Cancer
Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

Authors

  1. Address correspondence and reprint requests to Ignace Vergote, MD, PhD, University Hospitals, Leuven, European Union. E-mail: ignace.vergote{at}uz.kuleuven.ac.be.

Citation

Vergote I, Finkler NJ, Hall JB, et al
Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
International Journal of Gynecologic Cancer 2010;20:772-780.

Publication history

  • Received January 2, 2010
  • First published June 1, 2010.
Online issue publication 
March 06, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright © 2010 by IGCS and ESGO